整合下一代测序至内镜逆行胰胆管造影获取的胆道标本可改善恶性胆管狭窄的检测与管理
该前瞻性研究评估28基因NGS panel(BiliSeq)对252例胆管狭窄患者346份ERCP胆道标本的诊断效能。BiliSeq敏感度73%、特异度100%,联合病理评估敏感度升至83%、特异度99%,在原发性硬化性胆管炎患者中敏感度83%远高于病理评估的8%。20例(8%)检出治疗相关基因组变异,2例ERBB2扩增胆管癌接受曲妥珠单抗方案后获临床影像学缓解。
要点
- BiliSeq联合病理评估将恶性狭窄检出敏感度提高至83%,特异度维持99%。
- 在原发性硬化性胆管炎患者中,BiliSeq敏感度83%,病理评估仅8%。
- 20例(8%)患者检出治疗相关基因组变异,2例ERBB2扩增者接受曲妥珠单抗方案后获缓解。
核心结论
- BiliSeq联合胆道标本病理评估可提高恶性狭窄检出率,尤其在原发性硬化性胆管炎患者中;BiliSeq还可识别可能指导特定抗癌治疗的基因组变异。
研究设计与样本
- 前瞻性评估28基因NGS panel(BiliSeq)对ERCP获取的胆道标本的诊断效能,纳入252例胆管狭窄患者(57例训练集、195例验证集),共346份胆道标本,并与血清CA19-9及病理评估比较。
主要发现
- BiliSeq诊断恶性狭窄的敏感度为73%、特异度为100%;血清CA19-9升高敏感度76%、特异度69%;病理评估敏感度48%、特异度99%。
- BiliSeq联合病理评估将敏感度提高至83%,特异度维持99%。
- BiliSeq使胆道刷检病理评估的敏感度从35%提高至77%,使胆道活检的敏感度从52%提高至83%。
- 在原发性硬化性胆管炎患者中,BiliSeq敏感度为83%,病理评估敏感度为8%。
- 20例(8%)患者检出治疗相关基因组变异;2例ERBB2扩增胆管癌患者接受曲妥珠单抗方案后获得可测量的临床影像学缓解。
关键数值与推荐
- BiliSeq诊断恶性狭窄的敏感度73%、特异度100%。
- 血清CA19-9升高诊断恶性狭窄的敏感度76%、特异度69%。
- 病理评估诊断恶性狭窄的敏感度48%、特异度99%。
- BiliSeq联合病理评估的敏感度83%、特异度99%。
- 原发性硬化性胆管炎患者中BiliSeq敏感度83%,病理评估敏感度8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite improvements in imaging, serum CA19-9 and pathological evaluation, differentiating between benign and malignant bile duct strictures remains a diagnostic conundrum. Recent developments in next-generation sequencing (NGS) have opened new opportunities for early detection and management of cancers but, to date, have not been rigorously applied to biliary specimens. DESIGN: We prospectively evaluated a 28-gene NGS panel (BiliSeq) using endoscopic retrograde cholangiopancreatography-obtained biliary specimens from patients with bile duct strictures. The diagnostic performance of serum CA19-9, pathological evaluation and BiliSeq was assessed on 252 patients (57 trainings and 195 validations) with 346 biliary specimens. RESULTS: The sensitivity and specificity of BiliSeq for malignant strictures was 73% and 100%, respectively. In comparison, an elevated serum CA19-9 and pathological evaluation had sensitivities of 76% and 48%, and specificities of 69% and 99%, respectively. The combination of BiliSeq and pathological evaluation increased the sensitivity to 83% and maintained a specificity of 99%. BiliSeq improved the sensitivity of pathological evaluation for malignancy from 35% to 77% for biliary brushings and from 52% to 83% for biliary biopsies. Among patients with primary sclerosing cholangitis (PSC), BiliSeq had an 83% sensitivity as compared with pathological evaluation with an 8% sensitivity. Therapeutically relevant genomic alterations were identified in 20 (8%) patients. Two patients with ERBB2-amplified cholangiocarcinoma received a trastuzumab-based regimen and had measurable clinicoradiographic response. CONCLUSIONS: The combination of BiliSeq and pathological evaluation of biliary specimens increased the detection of malignant strictures, particularly in patients with PSC. Additionally, BiliSeq identified alterations that may stratify patients for specific anticancer therapies.
引用
- Singhi AD, Nikiforova MN, Chennat J, et al. Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut. 2019. PMID: 30971436. doi:10.1136/gutjnl-2018-317817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。